Actively Recruiting
Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
Led by Universidad Autonoma de Nuevo Leon · Updated on 2024-08-21
30
Participants Needed
1
Research Sites
71 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.
CONDITIONS
Official Title
Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of alopecia areata
- Less than 50% scalp hair loss (SALT score < 50%)
- No topical or systemic alopecia treatments in the last month
- Signed informed consent
You will not qualify if you...
- Any scalp skin condition (infectious, inflammatory, or cancerous) affecting clinical or trichoscopic features
- Pregnancy or breastfeeding
- Use of medications that may cause hair loss as a side effect
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital Universitario "Dr. José Eleuterio González"
Monterrey, Nuevo León, Mexico, 64460
Actively Recruiting
Research Team
E
Erika Alba-Rojas, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here